Langerhans cell histiocytosis (LCH) is a rare disorder in which a specific type of immune cell, normally found in the skin and mucous membranes, multiplies abnormally and accumulates in tissues throughout the body. These excess cells can form lesions that damage bone, skin, the lungs, the pituitary gland, and other organs. LCH affects roughly 2.6 to 8.9 children per million each year and is less common in adults, occurring at a rate of 1 to 2 per million annually.
What Happens Inside the Body
Langerhans cells are a normal part of your immune system. They sit in the outer layers of skin and in the linings of the mouth, lungs, and other surfaces, where they help detect foreign invaders and alert the rest of the immune system. In LCH, a genetic mutation causes these cells to grow out of control. Rather than quietly patrolling tissues, the abnormal cells pile up and recruit other immune cells, forming inflammatory masses that erode surrounding tissue.
The most commonly identified mutation involves a gene called BRAF, which sits within a signaling chain that tells cells when to grow and divide. When this gene is stuck in the “on” position, the cells keep multiplying without the usual stop signals. Because this mutation drives uncontrolled cell growth, LCH is now classified as a neoplastic (tumor-like) disorder rather than a simple immune overreaction, which is how it was understood for decades.
Who Gets LCH
LCH can appear at any age but is most common in children between 1 and 3 years old. Boys are slightly more affected than girls. In adults, one particular form of the disease, pulmonary LCH, has a striking association with cigarette smoking: 90 to 100 percent of adults diagnosed with lung-only LCH are smokers, often heavy ones consuming more than 20 cigarettes a day. Smoking cessation is considered essential in these cases, and disease resolution after quitting has been reported, though a few patients relapse even after stopping.
How LCH Is Classified
Doctors categorize LCH based on how many organ systems are involved, because this directly shapes treatment and outlook.
- Single-system LCH: Only one organ or system is affected. This could be a single bone lesion, multiple bone lesions, skin-only disease, or isolated involvement of a lymph node, the lungs, or the central nervous system. Most patients fall into this category.
- Multisystem LCH: Two or more organ systems are involved. The critical distinction here is whether “risk organs” are affected. The liver, spleen, and bone marrow are considered risk organs because their involvement signals a more aggressive disease course and a harder road to successful treatment.
Common Signs and Symptoms
LCH symptoms depend entirely on where the abnormal cells accumulate, which is part of why the disease is notoriously difficult to diagnose. It can mimic eczema, ear infections, or even cancer, depending on the site.
Bone
Bone lesions are the most frequent presentation. The majority of patients have a single bone lesion, though the disease can appear in multiple bones. Common locations include the skull, clavicle, pelvis, and spine. Children typically present with a painful, sometimes visible lump. Skull lesions may feel like a soft spot where bone has been destroyed.
Skin
About one-third of patients develop skin involvement. The rash consists of many small pinkish or reddish-brown bumps that often become crusted or infected. It tends to appear on the scalp, neck, armpits, groin, and trunk. In infants, scalp involvement can look nearly identical to cradle cap (seborrheic dermatitis), which often delays diagnosis. Ulcers in the mouth or on the genitals can also occur. Nails, palms, and soles are occasionally involved.
Lungs
Pulmonary LCH in adults typically causes a persistent cough and shortness of breath. The degree of airway obstruction tends to be worse than you would expect from cigarette consumption alone, because the lesions cluster around the small airways. Chest imaging often reveals a distinctive pattern of cysts and nodules in the upper and middle lung fields.
Pituitary Gland
LCH has a particular affinity for the pituitary gland, a small structure at the base of the brain that controls hormone production. The most common endocrine problem is diabetes insipidus, which develops in about 30 percent of patients. This is not the same as the more familiar diabetes mellitus. Instead, the body stops producing enough of a hormone that helps the kidneys retain water, leading to extreme thirst and frequent urination. Diabetes insipidus can appear before, during, or after the LCH diagnosis and is usually permanent.
How LCH Is Diagnosed
A definitive diagnosis requires a tissue biopsy. Under the microscope, pathologists look for two specific markers on the surface of the abnormal cells. One is a protein called CD1a, and the other is CD207 (also known as langerin), which is highly specific to Langerhans cells and correlates with the presence of distinctive rod-shaped structures inside the cells called Birbeck granules. Historically, identifying Birbeck granules under an electron microscope was the gold standard, but modern immunohistochemistry staining for CD1a and CD207 together has largely replaced that approach. Finding CD1a alone is not enough, because other cell types can also express it.
Once the diagnosis is confirmed, imaging and blood work help determine how many systems are involved and whether risk organs are affected. This staging process is what guides treatment decisions.
Treatment Approaches
Treatment ranges from simple observation to months of chemotherapy, depending on the extent of the disease.
A single bone lesion, for example, may be treated with curettage (scraping out the lesion) or sometimes a steroid injection directly into the site. Some isolated bone lesions resolve on their own. Skin-only disease in infants can also resolve without treatment, though it needs monitoring.
For multisystem disease or single-system disease that is widespread, the standard first-line treatment is a combination of two medications: a chemotherapy drug given by injection once per week and a steroid taken by mouth. The initial intensive phase lasts about six to seven weeks. If the disease responds, treatment continues in a maintenance phase with the same drugs given less frequently. The total recommended treatment duration is 12 months. Shorter courses were associated with higher relapse rates in clinical trials.
For adults with pulmonary LCH, quitting smoking is the single most important intervention. Some patients see their lung disease stabilize or improve after smoking cessation alone. Those whose disease progresses despite quitting may need systemic treatment.
Targeted therapies that block the specific mutated signaling pathway are increasingly used for patients who don’t respond to standard chemotherapy or who relapse. These drugs work by interrupting the overactive growth signal driving the abnormal cells.
Long-Term Effects and Outlook
Most cases of LCH resolve without lasting damage, but 30 to 40 percent of patients experience some form of permanent complication. The specific risks depend on which organs were involved and how extensive the disease was.
Hormone deficiencies are the most common long-term issue. Beyond diabetes insipidus, up to 10 percent of patients develop growth hormone deficiency, and some experience delayed puberty or other pituitary hormone losses. These conditions are manageable with hormone replacement but require lifelong monitoring.
Hearing loss can result from disease in the temporal bone (near the ear). Bone lesions in the skull and limbs usually heal without problems, but vertebral involvement can lead to spinal curvature, including scoliosis or kyphosis.
One of the more concerning late effects is neurodegenerative LCH, a slowly progressive neurological condition that can appear years after the original disease is treated. MRI scans detect characteristic brain changes in roughly 15 percent of multisystem LCH patients, usually long after treatment ends. Only about one in four of those patients go on to develop visible symptoms, which can include balance problems, slurred speech, difficulty concentrating, and learning difficulties. Because these changes can be subtle, regular neurological and neuropsychological evaluations are recommended for patients whose imaging shows early signs.
Prognosis varies widely. Patients with single-system disease, particularly a single bone lesion, have an excellent outlook. Multisystem disease without risk organ involvement also carries a favorable prognosis in most cases. The most serious outcomes are associated with multisystem disease involving the liver, spleen, or bone marrow, especially when the disease does not respond well to initial treatment. How quickly the disease responds in the first six weeks of therapy is one of the strongest predictors of long-term outcome.